The $300K Medical Device Rep

You can have two reps with the same title, working for similar companies, and one makes $150K while the other clears $300K.

Why?

It’s easy to say the higher earner is simply better at sales.

I don’t think it’s that simple.

The territory matters. The comp plan matters. Quota matters. Specialty, timing, existing business, product mix and whether you’re direct or distributor all matter.

Sometimes a lot.

Our early compensation data is starting to show just how wide that gap can be.

So instead of asking:

“How much do medical device reps make?”

I think there’s a better question:

What actually separates the $150K rep from the $300K+ rep?

Let’s get into it.

Territory Manager.

Sales Representative.

Account Executive.

The title might be the same. The opportunity underneath it can be completely different.

One rep inherits a multimillion-dollar territory with established surgeon relationships and predictable utilization.

Another inherits whitespace and an aggressive quota based on business that doesn’t exist yet.

One $250K OTE sits behind a realistic number with strong accelerators.

Another requires a quota very few people actually hit.

Same title. Very different W-2.

There are a handful of variables I’d want to understand before comparing any two device sales jobs:

Territory: What did the business actually produce last year? Is it growing? How concentrated is the revenue?

Quota: How was the number created? How quickly has quota increased compared with actual territory growth?

Comp plan: Commission rate, accelerators, thresholds, bonuses, caps and splits can completely change what strong performance is worth.

Specialty: The economics of spine, sports medicine, capital equipment, robotics, cardiovascular and other specialties can look very different.

Product mix: Recurring disposables behave differently than implants. Implants behave differently than capital.

Direct vs. distributor: Different upside, different risk, different benefits and often a completely different expense structure.

Existing business: Are you being paid to manage and grow an established territory, or are you being asked to build one?

Two reps can work equally hard and have very different W-2s.

That’s one of the realities of this industry that doesn’t get talked about enough.

You aren’t just choosing a job. You’re choosing the economic structure attached to it.

We're now at 54 anonymous submissions spanning a wide range of roles and specialties. It's still early, but the data is starting to tell a story.

The most common total compensation range is still $100K–$124,999, with 12 respondents landing there. But zoom out to the other end of the spectrum, and things get wild: exactly one-third of all respondents reported total W-2 compensation of $300K or more, 7 in the $300K–$399K range, and another 11 clearing $400K+.

Let that sink in: this single dataset includes reps earning under $100K and reps earning over $400K. All of them would answer "medical device sales" if you asked what they do for work. That's not a spread, that's practically two different careers wearing the same job title.

Pay structure tells its own story of variety:

Here's where it gets more interesting. Among the 43 respondents who reported quota attainment, the median was 104%. So we're not looking at a dataset full of reps missing quota and venting about their paychecks; these are, by and large, people who are hitting their numbers.

And yet, among the 51 who answered whether they feel fairly compensated:

23 said yes.
18 said no.
10 weren't sure.

That's just 45% who currently believe they're being paid fairly, despite performing at or above quota, on average. We'll need a much bigger sample before we can say why that gap exists. But that's exactly the question I want this database to eventually help answer.

Not just: What do medical device reps make?

But: What should someone with your role, specialty, geography, experience level, and performance reasonably expect to make?

If I could ask only one question before accepting a new territory, it wouldn't be about the offer. It would be this:

"What did the person covering this territory before me actually earn?"

Not the OTE. Not what the #1 rep in the country made. Not what I could make if every deal closes and every stroke of luck breaks my way.

What did this territory actually produce? What was quota? What did the previous rep attain? And what did that performance actually pay, in real dollars?

I've watched plenty of great-looking opportunities lose their shine the moment someone starts digging into territory history, quota, and actual attainment. OTE is a recruiting number, built to get you excited and get you signed. I want to know what the territory actually pays real humans who've worked it.

So before taking a new opportunity, here are five questions I'd want answered, no exceptions:

Because the real question isn't "What can I make?"

It's "What has to be true for me to make it?"

That's a much more useful conversation, and it's the one that actually tells you whether the job is worth taking.

Here's another variable I think is going to matter more over the next several years: where your cases are actually happening.

CMS expanded ASC eligibility in 2026 to include cardiac ablation, posterior lumbar fusion, and additional vascular procedures, while also increasing ASC payment rates by 2.6%. Orthopedics is already much further along in this transition, and I think the interesting question for reps is what happens to a territory once that volume starts to move.

A territory built around a handful of major hospitals could gradually turn into a hospital plus multiple affiliated or independent ASCs. That means more facilities to cover, different purchasing decision-makers to win over, different pricing pressure, more inventory movement, different capital economics, and potentially more case coverage overall. Maybe most importantly, it means different rules around who actually gets credit for the revenue.

The companies that look best positioned for this shift aren't just dragging their hospital products into smaller buildings. They're building entire commercial models around the specific economics of the ASC.

Our research put Zimmer Biomet, Stryker, and Smith+Nephew in the top tier for overall ASC positioning, with Enovis and Arthrex also standing out among the more ASC-native orthopedic players. Stryker, for instance, has more than 300 Mako systems reported in ASCs, and its Mako RPS was designed specifically with ASC footprint and economics in mind. Smith+Nephew reported that 40% of its 2025 CORI placements went to ASCs, climbing to 45% by Q4. Arthrex, meanwhile, brings decades of ASC relationships, a broad sports medicine portfolio, and its ASC X infrastructure strategy to the table.

If I were evaluating a territory with meaningful ASC exposure today, here's where I'd start:

What percentage of the business already comes from ASCs? How quickly is that changing? Who owns those accounts right now?

And the question that matters most: if volume shifts from my hospital into an affiliated ASC, who gets credit for the revenue?

That last question could eventually matter to your paycheck just as much as the industry trend itself.

Want the deeper analysis?

We ranked 12 major MedTech companies across six dimensions of ASC readiness in our full 2026 MedTech ASC Power Rankings.

One anonymous respondent recently told us:

"Current compensation structure emphasizes setting up new accounts as opposed to the quality of accounts. We are compensated the same for setting up an account that treats one patient a month versus one that treats 12 patients a month."

That's a fascinating problem, and it's worth sitting with for a second.

If you pay heavily for opening accounts, reps are going to chase openings. That's simply how incentives work. But if the real goal is long-term utilization and recurring revenue, shouldn't the plan reward the quality of the account too, not just its existence?

Comp plans ultimately tell reps what the organization actually values, regardless of what the mission statement says. And when the incentive doesn't line up with the actual business objective, you can't be too surprised when rep behavior doesn't line up either.

We’re still early.

Every anonymous submission makes the data more useful and gets us closer to meaningful comparisons by role, specialty, geography, experience and compensation structure.

It takes about three minutes and remains anonymous.

CONTRIBUTE TO THE COMPENSATION INDEX

If you know another rep who would find this useful, forward it to them.

And if there’s something about compensation, territories or careers in this industry that nobody seems to talk about honestly, reply to this email.

I read every response.

The Med Device Rep
TheMedDeviceRep.com